Summary
A feasibility study of neoadjuvant chemotherapy (NAC) followed by interval cytoreductive surgery (ICS) and postoperative chemotherapy for stage III/IV mullerian carcinomas such as ovarian, tubal and peritoneal carcinomas.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * Stage III or IV müllerian carcinoma by prelaparoscopic clinical findings including imaging studies (CT, MRI or ultrasonography) * Cytology of ascites, pleural effusions, or fluids obtained by tumor centesis * Malignancies of other origins, such as breasts and digestive tract, should be excluded by endoscopy, opaque enema, or ultrasonography when these malignancies are suspected from symptoms, physical examinations or imaging diagnosis. * CA125\>200U/ml and CEA\<20ng/ml. * Clinically deemed to be a candidate for debulking surgery without evidence of brain, bone, bone marrow metastases, multiple lung, or multiple liver metastases * Presence of at least one measurable lesion * Previously untreated for these malignancies and no history of treatment with chemotherapy or radiotherapy even for other diseases * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3, * Adequate bone marrow, hepatic, renal, cardiac and respiratory functions, and * Written informed consent. Exclusion Criteria: * Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ * Pregnant or nursing * Severe mental disorders * Systemic and continuous use of steroidal drugs * Active infections * Uncontrolled hypertension * Diabetes mellitus, uncontrolled or controlled with insulin * History of cardiac failure, unstable angina, myocardial infarction within 6 months prior to the registration * Liver cirrhosis or bleeding tendency contraindicating debulking surgery * Intestinal occlusion necessary for surgical treatment * Hypersensitivity to alcohol